Cargando…

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?

Immunotherapy using checkpoint inhibitor targeting PD-1 and PD-L1 revolutionized the treatment of microsatellite instable metastatic colon cancer. Such treatment is now a standard of care for these patients. However, when used as monotherapy checkpoint inhibitors targeting PD-1 and PD-L1 are not eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghiringhelli, François, Fumet, Jean-David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691024/ https://www.ncbi.nlm.nih.gov/pubmed/31447840 http://dx.doi.org/10.3389/fimmu.2019.01816

Ejemplares similares

Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
por: Thibaudin, Marion, et al.
Publicado: (2023)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives
por: Gandini, Annalice, et al.
Publicado: (2023)

Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial
por: Fumet, Jean-David, et al.
Publicado: (2017)

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
por: Pecci, Federica, et al.
Publicado: (2021)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2022)

Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer
por: Zhou, Long, et al.
Publicado: (2023)

Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer
por: Kim, Chang Woo, et al.
Publicado: (2021)

Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives
por: Motta, Rodrigo, et al.
Publicado: (2021)

Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer
por: Ding, Yuwei, et al.
Publicado: (2023)

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
por: Fumet, Jean-David, et al.
Publicado: (2018)

Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer
por: Cohen, Romain, et al.
Publicado: (2021)

Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine
por: Huyghe, Nicolas, et al.
Publicado: (2022)

Opportunities for immunotherapy in microsatellite instable colorectal cancer
por: Westdorp, Harm, et al.
Publicado: (2016)

The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer
por: Hermel, David J., et al.
Publicado: (2019)

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
por: Bellio, Hélène, et al.
Publicado: (2021)

The expressed mutational landscape of microsatellite stable colorectal cancers
por: Sveen, Anita, et al.
Publicado: (2021)

Case report: A colorectal cancer patient with microsatellite instability-high and MSH2 germline mutation failed to respond to anti-PD-1 immunotherapy
por: Zhang, Qun, et al.
Publicado: (2022)

Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy
por: Fumet, Jean-David, et al.
Publicado: (2020)

Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer
por: Akce, Mehmet, et al.
Publicado: (2023)

Radiation Therapy Enhances Immunotherapy Response in Microsatellite-stable Colorectal and Pancreatic Adenocarcinoma in a Phase II Trial
por: Parikh, Aparna R., et al.
Publicado: (2021)

Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report
por: Lin, Sen, et al.
Publicado: (2022)

Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma
por: San-Román-Gil, María, et al.
Publicado: (2023)

Chromosomal Instability in BRAF Mutant, Microsatellite Stable Colorectal Cancers
por: Bond, Catherine E., et al.
Publicado: (2012)

Colorectal Cancer Immunotherapy: Options and Strategies
por: Johdi, Nor Adzimah, et al.
Publicado: (2020)

SnoN expression is differently regulated in microsatellite unstable compared with microsatellite stable colorectal cancers
por: Chia, June A, et al.
Publicado: (2006)

Immunological features of coronavirus disease 2019 in patients with cancer
por: Thibaudin, Marion, et al.
Publicado: (2020)

Mitochondrial microsatellite instability in patients with metastatic colorectal cancer
por: Venderbosch, S., et al.
Publicado: (2015)

Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
por: Matteucci, Laura, et al.
Publicado: (2023)

The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer
por: Sillo, Toritseju O., et al.
Publicado: (2023)

Correction: Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Publicado: (2021)

Complement System: An Immunotherapy Target in Colorectal Cancer
por: Talaat, Iman M., et al.
Publicado: (2022)

Mechanism and strategies of immunotherapy resistance in colorectal cancer
por: Shan, Jiqi, et al.
Publicado: (2022)

Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2022)

Transcriptome and Network Dissection of Microsatellite Stable and Highly Instable Colorectal Cancer
por: Akbari, Vahid, et al.
Publicado: (2019)

Tertiary lymphoid structures in pulmonary metastases of microsatellite stable colorectal cancer
por: Karjula, Topias, et al.
Publicado: (2023)

Editorial: New therapeutic approaches in microsatellite stable colorectal cancer patients
por: Bartolini, Michela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ei78818vrkndi0lgo8avsclktl